A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies–Emphasis on Alzheimer’s Disease Pathogenesis
Issued Date
2022-05-01
Resource Type
ISSN
03643190
eISSN
15736903
Scopus ID
2-s2.0-85124320041
Pubmed ID
35122609
Journal Title
Neurochemical Research
Volume
47
Issue
5
Start Page
1166
End Page
1182
Rights Holder(s)
SCOPUS
Bibliographic Citation
Neurochemical Research Vol.47 No.5 (2022) , 1166-1182
Suggested Citation
Shukla M. A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies–Emphasis on Alzheimer’s Disease Pathogenesis. Neurochemical Research Vol.47 No.5 (2022) , 1166-1182. 1182. doi:10.1007/s11064-022-03530-2 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83756
Title
A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies–Emphasis on Alzheimer’s Disease Pathogenesis
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Numerous challenges are confronted when it comes to the recognition of therapeutic agents for treating complex neurodegenerative diseases like Alzheimer’s disease (AD). The perplexing pathogenicity of AD embodies cholinergic dysfunction, amyloid beta (Aβ) aggregation, neurofibrillary tangle formation, neuroinflammation, mitochondrial disruption along with vicious production of reactive oxygen species (ROS) generating oxidative stress. In this frame of reference, drugs with multi target components could prove more advantageous to counter complex pathological mechanisms that are responsible for AD progression. For as much as, medicinal plant based pharmaco-therapies are emerging as potential candidates for AD treatment keeping the efficacy and safety parameters in terms of toxicity and side effects into consideration. Huperzine A (Hup A) is a purified alkaloid compound extracted from a club moss called Huperzia serrata. Several studies have reported both cholinergic and non-cholinergic effects of this compound on AD with significant neuroprotective properties. The present review convenes cumulative demonstrations of neuroprotection provided by Hup A in in vitro, in vivo, and human studies in various pathologies. The underlying molecular mechanisms of its actions have also been discussed. However, more profound evidence would certainly promote the therapeutic implementation of this drug thus furnishing decisive insights into AD therapeutics and various other pathologies along with preventive and curative management.